Oppenheimer analyst Kevin DeGeeter lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $37.00 (from $45.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Taysha Gene Therapies (TSHA) PT Lowered to $31 at JefferiesApril 1, 2022 8:46 AM Taysha Gene Therapies (TSHA) PT Lowered to $35 at Truist SecuritiesApril 1, 2022 7:26 AM Taysha Gene Therapies (TSHA) PT Lowered to $25 at BTIGApril 1, 2022 6:25 AM Taysha Gene Therapies (TSHA) PT Lowered to $36 at JMP SecuritiesApril 1, 2022 2:19 AM Form S-8 Taysha Gene Therapies, March 31, 2022 4:33 PM Form 424B5 Taysha Gene Therapies, March 31, 2022 4:32 PM Taysha Gene Therapies (TSHA) PT Lowered to $22 at WedbushMarch 31, 2022 1:31 PM Taysha Gene Therapies (TSHA) PT Lowered to $32 at Needham & CompanyMarch 31, 2022 12:46 PM Form 10-K Taysha Gene Therapies, For: Dec 31March 31, 2022 9:09 AM Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7cMarch 31, 2022 7:35 AM